The overall 5-year survival rate for stage 4 lung cancer is 10.5%, meaning roughly 1 in 10 people diagnosed at this stage are alive five years later. But that single number obscures a wide range of outcomes. Some people live months, others live years, and the difference depends heavily on the type of lung cancer, its genetic profile, and how well you’re functioning at diagnosis.
What the Overall Numbers Show
Stage 4 means the cancer has spread beyond the lungs to distant parts of the body. About 51% of all lung cancer cases are already at this stage when first detected. The SEER database, which tracks cancer outcomes across the United States, reports a 5-year relative survival rate of 10.5% for distant-stage lung and bronchus cancer, based on cases diagnosed between 2016 and 2022.
That figure blends together every type of lung cancer, every treatment approach, and every patient regardless of age or health. It’s a starting point, not a prediction. Your individual outlook can be significantly better or worse depending on several factors covered below.
Non-Small Cell vs. Small Cell Lung Cancer
The two main types of lung cancer behave very differently at stage 4, and the distinction matters more for survival than almost anything else.
Non-small cell lung cancer (NSCLC) accounts for roughly 80 to 85% of all lung cancers. It tends to grow more slowly, responds to a broader range of treatments, and generally carries a longer life expectancy at stage 4. Median survival with modern therapies ranges from about one year to well over four years, depending on the tumor’s molecular characteristics and how it responds to treatment.
Small cell lung cancer (SCLC) is more aggressive. When it reaches the extensive stage (the small cell equivalent of stage 4), median survival is 6 to 12 months with current therapy, and long-term disease-free survival is rare. Small cell tumors initially respond well to chemotherapy, but they tend to return quickly.
Stage 4A vs. Stage 4B
Stage 4 is split into two substages that reflect how far the cancer has traveled. Stage 4A means the cancer has spread to the other lung, the lining of the lungs or heart, the fluid around those organs, or to a single site outside the chest, such as a bone or an adrenal gland. Stage 4B means the cancer has reached multiple sites outside the chest.
The distinction is straightforward: fewer areas of spread generally mean more treatment options and a better prognosis. A person with a single brain metastasis that can be targeted with radiation, for instance, faces a very different situation than someone with cancer in the bones, liver, and brain simultaneously.
How Genetic Testing Changes the Picture
One of the biggest shifts in stage 4 lung cancer survival has come from identifying specific genetic mutations in tumors and matching them with targeted drugs. If your tumor carries an EGFR mutation (one of the most common treatable mutations in NSCLC), targeted therapy can dramatically extend survival. In real-world data, patients with EGFR-mutated tumors who received targeted treatment had a median overall survival of nearly 55 months, compared to about 23 months for those with the same mutation who did not receive targeted therapy.
EGFR is just one of several actionable mutations. Tumors can also carry changes in ALK, ROS1, BRAF, KRAS, and other genes, each with its own set of targeted drugs. This is why molecular testing of the tumor at diagnosis is so important. Two people with stage 4 NSCLC can have radically different survival timelines based on whether their cancer has a targetable mutation and whether it’s identified early enough to act on.
The Impact of Immunotherapy
For stage 4 NSCLC patients whose tumors don’t carry a targetable mutation, immunotherapy has become a cornerstone of treatment. These drugs work by helping your immune system recognize and attack cancer cells. The results have been particularly striking for patients whose tumors produce high levels of a protein called PD-L1, which normally shields cancer from immune detection.
In a landmark clinical trial, patients with high PD-L1 levels who received immunotherapy had a 5-year survival rate of 31.9%, compared to 16.3% for those treated with chemotherapy alone. Median survival was 26.3 months with immunotherapy versus 13.4 months with chemotherapy. Among patients who completed a full two-year course of immunotherapy, the survival rate at roughly five years from the start of treatment was 81.4%. That’s a remarkable number for a disease that was almost universally fatal within a year just two decades ago.
Not everyone responds this well. Immunotherapy works best when PD-L1 levels are high and the tumor has a high number of genetic mutations. For patients with low or no PD-L1 expression, immunotherapy is often combined with chemotherapy, and the benefit is more modest.
Factors That Affect Your Individual Outlook
Beyond cancer type and treatment options, several personal factors shape how long someone lives with stage 4 lung cancer.
- Performance status. This is a measure of how well you can carry out daily activities. People who are still active and able to care for themselves tolerate treatment better and live longer than those who are bedridden or need significant help. Patients with poor functional status are often excluded from clinical trials entirely, which means the survival numbers you see in studies may overestimate outcomes for people who are already quite ill at diagnosis.
- Where the cancer has spread. Metastases in the brain or liver tend to carry a worse prognosis than spread limited to the bones or the other lung. The number of metastatic sites also matters.
- Age and other health conditions. Younger patients and those without serious conditions like heart disease or COPD generally tolerate aggressive treatment better. But age alone doesn’t disqualify someone from benefiting from modern therapies.
- Response to initial treatment. How the cancer reacts to the first round of treatment is one of the strongest predictors of long-term survival. A tumor that shrinks substantially in the first few months signals a better trajectory.
Why Averages Can Be Misleading
Survival statistics are drawn from large populations and always lag behind the latest treatments. The 10.5% five-year survival rate from SEER includes patients diagnosed as far back as 2016, many of whom may not have received the newest immunotherapies or targeted drugs. A person diagnosed today with a treatable mutation or high PD-L1 expression has a meaningfully better outlook than that number suggests.
Median survival is another commonly cited figure, and it’s important to understand what it actually means. A median of 12 months doesn’t mean everyone dies around one year. It means half the people in that group lived longer and half lived shorter. Some in the longer-lived half survive three, five, or even ten years. The tail of the survival curve, where a smaller group of patients continues to do well for years, has been growing steadily as new treatments emerge.
The honest answer to “how long can you live with stage 4 lung cancer” is that it varies enormously. For extensive-stage small cell lung cancer, timelines are typically measured in months. For NSCLC with a targetable mutation or strong immunotherapy response, many patients now live multiple years, and a meaningful minority reach the five-year mark and beyond. The single most important step after diagnosis is comprehensive molecular testing of the tumor, which opens the door to the treatments most likely to extend survival.